<?xml version="1.0" encoding="UTF-8"?>
<p>To further test the capacity of inflammatory monocytes to mount an antiviral response and protect against RRV infection 
 <italic>in vivo</italic>, we generated 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> and CCR2-DTR → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> bone marrow chimeras. 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice produce undetectable levels of type I IFN following alphavirus infection and are therefore highly susceptible to severe disease [
 <xref rid="ppat.1006748.ref051" ref-type="bibr">51</xref>, 
 <xref rid="ppat.1006748.ref052" ref-type="bibr">52</xref>]. Thus, this system tests the capacity of hematopoietic cells to protect from RRV infection in an IRF3/IRF7-dependent manner. To determine the percent chimerism in 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice reconstituted with CCR2-DTR bone marrow, we took advantage of the fact that the CCR2-DTR allele also encodes CFP by using flow cytometry to analyze CFP expression in circulating monocytes (
 <xref ref-type="supplementary-material" rid="ppat.1006748.s010">S10 Fig</xref>). At 5 weeks post-reconstitution, circulating monocytes were &gt; 90% CFP-positive in all of the CCR2-DTR → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> bone marrow chimeras (
 <xref ref-type="supplementary-material" rid="ppat.1006748.s010">S10 Fig</xref>). Bone marrow chimeric mice were i.p. administered PBS or DT one day prior and two days after inoculation with RRV-T48-nsP1
 <sup>6M</sup>. As expected, 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice developed severe disease and were humanely euthanized at 5–6 dpi (
 <xref ref-type="fig" rid="ppat.1006748.g010">Fig 10A and 10B</xref>). In contrast, CCR2-DTR → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice treated with PBS were protected against severe RRV disease (
 <xref ref-type="fig" rid="ppat.1006748.g010">Fig 10A and 10B</xref>), indicating that IRF3 and IRF7 sufficient hematopoietic cells can protect 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice against RRV-T48-nsP1
 <sup>6M</sup> infection. Treatment of CCR2-DTR → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice with DT resulted in more severe disease signs (
 <xref ref-type="fig" rid="ppat.1006748.g010">Fig 10A and 10B</xref>) and higher viral loads in skeletal muscle tissue (
 <xref ref-type="fig" rid="ppat.1006748.g010">Fig 10C</xref>) compared with CCR2-DTR → 
 <italic>Irf3</italic>
 <sup>
  <italic>-/-</italic>
 </sup>
 <italic>;Irf7</italic>
 <sup>-/-</sup> mice that did not receive DT. These data suggest that CCR2
 <sup>+</sup> hematopoietic cells, including inflammatory monocytes, can protect from RRV infection via a type I IFN-dependent mechanism.
</p>
